Q2 2026 saw a 3% revenue increase and robust cash flow, but EBITDA declined 1% year-over-year due to higher costs and a NOK 337 million impairment. Segment results were mixed, with Fine Chemicals outperforming, while BioSolutions faced margin pressure.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.